Literature DB >> 22173751

Neuroradiologic correlates of cognitive impairment in adult Moyamoya disease.

M A Mogensen1, P Karzmark, P D Zeifert, J Rosenberg, M Marks, G K Steinberg, L J Dorfman.   

Abstract

BACKGROUND AND
PURPOSE: MMD has been shown to result in impairment of executive functioning in adults. The purpose of this study was to correlate presurgical neuropsychological assessments with the severity of primary MMD as measured by CBF and CVR and with secondary damage from MMD as estimated by cortical stroke and WMD.
MATERIALS AND METHODS: A retrospective analysis of 31 adult patients with MMD was performed. Xe-CT was used to obtain CBF and CVR, and MRI was reviewed to grade cortical stroke and WMD. Two tests of executive functioning (FAS and TMT-B) were correlated with imaging findings. A multiple regression analysis was performed.
RESULTS: There was a significant overall positive relationship between mean CBF and FAS (P = .038) and TMT-B scores (P = .014). A significant negative relationship was present between the WMD score and the FAS (P = .009) and TMT-B scores (P = .015). Per-region analysis demonstrated that FAS and TMT-B scores were significantly decreased by the presence of a posterior stroke (P < .0001 and P = .001) or WMD (P = .006 and P = .004). All patients with posterior parieto-occipital WMD or stroke also had secondary disease in the anterior regions.
CONCLUSIONS: Impaired executive functioning in adults with MMD is most strongly associated secondary damage in the form of WMD or cortical stroke. The effect is most profound with parieto-occipital lobe involvement, likely a reflection of overall disease severity. Increasing global WMD burden may be a better indicator of cognitive decline than cortical infarction. Patients with higher baseline CBF seem to have better cognitive functioning.

Entities:  

Mesh:

Year:  2011        PMID: 22173751      PMCID: PMC8050434          DOI: 10.3174/ajnr.A2852

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  17 in total

1.  Neuropsychological and perfusion MR imaging correlates of revascularization in a case of moyamoya syndrome.

Authors:  A L Jefferson; G Glosser; J A Detre; G Sinson; D S Liebeskind
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

2.  Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

Authors:  J Suzuki; A Takaku
Journal:  Arch Neurol       Date:  1969-03

3.  Moyamoya disease--a review.

Authors:  J Suzuki; N Kodama
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

4.  Mental outcome following encephaloduroarteriosynangiosis in children with moyamoya disease with the onset earlier than 5 years of age.

Authors:  Y Matsushima; M Aoyagi; H Masaoka; R Suzuki; K Ohno
Journal:  Childs Nerv Syst       Date:  1990-12       Impact factor: 1.475

5.  Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it?

Authors:  S Kuroda; K Houkin; H Kamiyama; K Mitsumori; Y Iwasaki; H Abe
Journal:  Stroke       Date:  2001-09       Impact factor: 7.914

6.  Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.

Authors:  T Yamauchi; M Tada; K Houkin; T Tanaka; Y Nakamura; S Kuroda; H Abe; T Inoue; K Ikezaki; T Matsushima; M Fukui
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

7.  Changing ischaemic lesion patterns in adult moyamoya disease.

Authors:  J-M Kim; S-H Lee; J-K Roh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-05-01       Impact factor: 10.154

8.  Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc-HMPAO SPECT and acetazolamide in childhood Moyamoya disease.

Authors:  H Touho; J Karasawa; H Ohnishi
Journal:  Stroke       Date:  1996-02       Impact factor: 7.914

9.  Autosomal dominant moyamoya disease maps to chromosome 17q25.3.

Authors:  Y Mineharu; W Liu; K Inoue; N Matsuura; S Inoue; K Takenaka; H Ikeda; K Houkin; Y Takagi; K Kikuta; K Nozaki; N Hashimoto; A Koizumi
Journal:  Neurology       Date:  2008-05-07       Impact factor: 9.910

Review 10.  The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia.

Authors:  A S Vagal; J L Leach; M Fernandez-Ulloa; M Zuccarello
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-26       Impact factor: 3.825

View more
  4 in total

1.  Preliminary study of neurocognitive dysfunction in adult moyamoya disease and improvement after superficial temporal artery-middle cerebral artery bypass.

Authors:  Hyun Joo Baek; Seung Young Chung; Moon Sun Park; Seong Min Kim; Ki Suk Park; Hee Un Son
Journal:  J Korean Neurosurg Soc       Date:  2014-09-30

Review 2.  Late Cerebrovascular Events and Social Outcome after Adolescence: Long-term Outcome of Pediatric Moyamoya Disease.

Authors:  Takeshi Funaki; Jun C Takahashi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-21       Impact factor: 1.742

3.  Cognitive Functions in Children and Adults with Moyamoya Vasculopathy: A Systematic Review and Meta-Analysis.

Authors:  Annick Kronenburg; Esther van den Berg; Monique M van Schooneveld; Kees P J Braun; Lionel Calviere; Albert van der Zwan; Catharina J M Klijn
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967

4.  Decreased frontal white-matter diffusion and improved cognitive flexibility after burr-hole surgery in moyamoya angiopathy.

Authors:  Lionel Calviere; Paul Loubiere; Melanie Planton; Vanessa Cazzola; Isabelle Catalaa; Helene Mirabel; Jean Christophe Sol; Fabrice Bonneville
Journal:  BMC Neurol       Date:  2020-01-20       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.